0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Invited Commentary |

Measuring the Effectiveness of Androgen-Deprivation Therapy for Prostate Cancer in the Medicare Population:  Adequate Data Are Neither the Same as Nor the Enemy of Perfect Data

Quoc-Dien Trinh, MD, FRCSC1,2; Deborah Schrag, MD, MPH1
[+] Author Affiliations
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
2Division of Urologic Surgery, Brigham and Women’s Hospital, Boston, Massachusetts
JAMA Intern Med. 2014;174(9):1468-1469. doi:10.1001/jamainternmed.2014.1107.
Text Size: A A A
Published online

Extract

In the late 1970s, investigators learned that androgen-deprivation therapy (ADT) decreased serum testosterone levels and, more importantly, reduced bone pain among men with prostate cancer. Whereas ADT demonstrated benefit in patients with metastatic disease and as an adjunct to radiation therapy in patients with locally advanced disease, its use at the organ-confined stage has never been supported by evidence or expert guidelines. Most importantly, randomized data have shown that immediate ADT for nonmetastatic prostate cancer not only lacks a survival benefit but may cause harm, such as an excess risk of bone fractures.1 Nevertheless, the use of ADT for localized prostate cancer increased greatly between the 1990s and early 2000s with compelling evidence that favorable reimbursement contributed to this trend.2

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
Jobs
brightcove.createExperiences();